Cadila Healthcare stock: Analysts see 20% compounded growth in US sales

The Cadila Healthcare stock price has corrected by a fourth since its high touched in November and by almost a third from its peak level reached in June last year.
 
Concerns over rising competitive intensity in the US and pricing pressure in the pharma sector are weighing on the company’s stock prices.
 
While analysts have cut their forward net profit estimates to factor in the challenges, the correction in stock prices, according to them, is exaggerated.
 
Analysts at Nomura, while maintaining their positive stance on Cadila, said the fall in stock prices was significantly higher than the